Dilon Technologies Closes First Quarter With Record Sales

NEWPORT NEWS, Va., April 11 /PRNewswire/ -- Dilon Technologies, Inc., a manufacturer and supplier of highresolution molecular imaging systems, announced today that nine additional Dilon 6800 orders have been secured to close out the end of the first quarter.

The Dilon 6800, a high-resolution, small field-of-view gamma camera, optimized to perform Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique used for the early detection of breast cancer will be installed in various leading medical centers nationally and internationally.

"We are only at the start of our company's growth cycle, but it is gratifying to witness that an increasing number of medical institutions, on a worldwide basis, are beginning to recognize the clinical and economic advantages that our system affords them," said Robert G. Moussa, Chairman and CEO.

About Dilon Technologies, Inc.

Dilon Technologies, Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.

SOURCE Dilon Technologies, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.